Table 6.
Oncolytic virus therapy for breast cancer in the recruitment phase
| Agents | Trial / Phase | Setting |
|---|---|---|
| Pelareorep, letrozole, atezolizumab, trastuzumab | A Window-of-Opportunity Study of Pelareorep in Early Breast Cancer / Phase 1 | Neoadjuvant |
| Ipilimumab, nivolumab, talimogene, laherparepvec | Ipilimumab, Nivolumab, and Talimogene Laherparepvec before Surgery in Treating Participants with Localized, Triple-Negative or Estrogen Receptor-Positive, HER2-Negative Breast Cancer-Deleted / Phase 1 | Neoadjuvant |
| Paclitaxel, pelareorep, avelumab | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with Anti-PD-L1 Avelumab and Paclitaxel − BRACELET-1 Study / Phase 2 | Metastatic |
| ADV/HSV-tk, valacyclovir, radiation: SBRT, pembrolizumab | SBRT and Oncolytic Virus Therapy before Pembrolizumab for Metastatic TNBC and NSCLC / Phase 2 | Metastatic |
| PVSRIPO | Examining Bioactivity of PVSRIPO in Invasive Breast Cancer / Phase 1 | Metastatic |
| Pelareorep, retifanlimab | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple-Negative Breast Cancer, IRENE Study / Phase 2 | Metastatic |
| Cyclophosphamide and JX-594 dose escalation, cyclophosphamide and JX-594, cyclophosphamide | A Study of Metronomic CP and JX-594 in Patients with Advanced Breast Cancer and Advanced Soft-Tissue Sarcoma (METROmaJX) / Phases 1 and 2 | Metastatic |
| TBio-6517, pembrolizumab | Study of TBio-6517, Given Intratumorally, Alone or in Combination with Pembrolizumab, in Solid Tumors / Phases 1 and 2 | Metastatic |
| ONCR-177, pembrolizumab | Study of ONCR-177 Alone and in Combination with PD-1 Blockade in Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors / Phase 1 | Metastatic |